CHICAGO, July 6, 2023 /PRNewswire/ — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to grant traditional approval of Leqembi™ (lecanemab, Eisai/Biogen) for the treatment of early Alzheimer’s disease. This is the first Alzheimer’s treatment granted traditional approval that changes the underlying course of the disease.…Read More
ALZHEIMERS ASSOCIATION WELCOMES US FDA TRADITIONAL APPROVAL OF LEQEMBI
